|
|
| Oncologie > Etude de marché sectorielle |
| Cancer Biomarkers: Enhancing diagnostic, therapeutic and developmental strategies |
|
|
|
|
€ 3 040,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Mai 2006 |
Taille du document : |
73 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 133 pages | Novembre 2002 | Anglais
|
|
|
| Main
focus: |
oncology,cancer,carcinoma,breast cancer,...,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,japan,china,united kingdom,germany,canada,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
MarketWatch: Cancer
33 pages | Mars 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: Cancer
32 pages | Juillet 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
Cancer Vaccines: Measuring Market Potential
232 pages | Octobre 2004 |
This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets.
Vaccine product candidates are discussed within the co |
1 200,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Octobre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail
71 pages | Janvier 2005 |
IntroductionRoche continues to lead the oncology sector, recording oncology sales of $5,719m in 2003.
This sector dominance is predicted to continue between 2004 and 2010, due to Roche's ability to |
3 040,00 €
|
| |
| |
Pipeline Insight: Cancer Vaccines and Cell Therapies - Technical Know How Needs Translation Into Clinical and Commercial Rewards
203 pages | Avril 2005 |
IntroductionUnmet need across the cancer market is high, with most therapies conferring low levels of specificity and high toxicity.
Development of cancer vaccines may be the holy grail, with the p |
9 120,00 €
|
| |
| |
Commercial Insight Top 20 Cancer Therapeutics
197 pages | Juillet 2006 |
IntroductionThe Top 20 cancer therapeutics generated sales of $20.1 billion in 2005 across the seven markets, set to reach $27.4 billion by 2015.
Cytotoxics currently constitute the majority, due t |
12 160,00 €
|
| |
| |
The Cancer Outlook 2000
128 pages | Septembre 2000 |
Driven by the cytotoxic, adjunct and innovative drug classes, the cancer market grew by 16% in 1999 to a global value of almost $19bn, and is now poised on the verge of a period of significant exp |
955,00 €
|
| |
| |
MarketWatch: Cancer
27 pages | Mai 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Décembre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Cancer Biomarkers: Enhancing diagnostic, therapeutic and developmental strategies |
|
|
Introduction
The current focus on biomarker discovery is a result of an improved understanding of the biologic basis for carcinogenesis. The increasing number of potential drug targets and a plethora of diverse, new developmental agents have stimulated the search for biomarkers that can reduce the time, cost and attrition rates prevalent in oncology drug development.
Scope
The role of biomarkers in optimizing patient selection and treatment outcomes and in expediting oncology drug development.
Biomarker classification in oncology.
Regulator opinion on the integration of novel, valid and relevant biomarker endpoints into the design of oncology clinical trials.
Key commercial benefits and risks of incorporating predictive biomarkers into oncology drug development.
Highlights
It is hoped that the increased adoption of biomarker use in oncology will enable early proof-of-concept studies for novel therapeutic targets; accelerate the adoption of population-enrichment strategies for clinical trial recruitment; and increase the use of biomarker endpoints as surrogates for clinical benefit in oncology clinical trials.
Advances in imaging analysis technology have shed new light on cancer progression by enabling the precise measurement of small changes in structure and function over time. Image-based biomarkers have been singled out by the FDA as promising tools for every stage of drug development, from preclinical research to the approval process.
While targeting specific genotypes in clinical trials increases the opportunity to demonstrate clinical benefit, developers are concerned about how an increasingly fragmented cancer market may limit a drug's commercial potential. There is already skepticism among physicians about how readily Pharma will adopt a more 'personalized' approach.
Reasons to Purchase
Understand how tumor biomarkers will impact on oncology drug development as the paradigm to targeted treatment evolves.
Assess opportunities and risks for novel oncology biomarker development and commercialization.
Drive drug development strategies that incorporate prognostic or predictive biomarkers.
|
|
Introduction
The current focus on biomarker discovery is a result of an improved understanding of the biologic basis for carcinogenesis. The increasing number of potential drug targets and a plethora of diverse, new developmental agents have stimulated the search for biomarkers that can reduce the time, cost and attrition rates prevalent in oncology drug development.
Scope
The role of biomarkers in optimizing patient selection and treatment outcomes and in expediting oncology drug development.
Biomarker classification in oncology.
Regulator opinion on the integration of novel, valid and relevant biomarker endpoints into the design of oncology clinical trials.
Key commercial benefits and risks of incorporating predictive biomarkers into oncology drug development.
Highlights
It is hoped that the increased adoption of biomarker use in oncology will enable early proof-of-concept studies for novel therapeutic targets; accelerate the adoption of population-enrichment strategies for clinical trial recruitment; and increase the use of biomarker endpoints as surrogates for clinical benefit in oncology clinical trials.
Advances in imaging analysis technology have shed new light on cancer progression by enabling the precise measurement of small changes in structure and function over time. Image-based biomarkers have been singled out by the FDA as promising tools for every stage of drug development, from preclinical research to the approval process.
While targeting specific genotypes in clinical trials increases the opportunity to demonstrate clinical benefit, developers are concerned about how an increasingly fragmented cancer market may limit a drug's commercial potential. There is already skepticism among physicians about how readily Pharma will adopt a more 'personalized' approach.
Reasons to Purchase
Understand how tumor biomarkers will impact on oncology drug development as the paradigm to targeted treatment evolves.
Assess opportunities and risks for novel oncology biomarker development and commercialization.
Drive drug development strategies that incorporate prognostic or predictive biomarkers.
|
|
|
PPLSEN
|
|
|
|
|
